Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS:    
Cash and cash equivalents $ 100,811 $ 2,857
Restricted cash 125 97
Short term bank deposits 100
Trade receivable 187 137
Prepaid expenses and other receivables 3,058 830
Total current assets 104,181 4,021
NON-CURRENT ASSETS:    
Property and equipment, net 1,165 384
Total non-current assets 1,165 384
Total assets 105,346 4,405
CURRENT LIABILITIES:    
Current maturities of long-term loan 1,879
Short-term loan 4,916
Trade payables 2,005 1,209
Employees and payroll accruals 3,095 1,538
Deferred revenue 726 281
Accrued expenses and other payables 4,725 364
Total current liabilities 15,467 5,271
LONG-TERM LIABILITIES:    
Long-term loan 676
Convertible loan 1,641
Warrant liabilities 10,056
Warrants to purchase Series B-1 preferred shares 375
Warrants to purchase Series B-2 preferred shares 1,159
Total long-term liabilities 10,056 3,851
REDEEMABLE CONVERTIBLE PREFERRED SHARES*:    
Seed redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 6,938,675 shares authorized as of December 31, 2020; 5,540,254 shares issued and outstanding as of December 31, 2020; 650
Series A redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 9,251,566 shares authorized as of December 31, 2020; 7,780,937 shares issued and outstanding as of December 31, 2020; 9,394
Series A-1 redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 6,938,675 shares authorized as of December 31, 2020; 5,460,043 shares issued and outstanding as of December 31, 2020; 2,500
Series B redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 12,258,325 shares authorized as of December 31, 2020; 10,863,143 shares issued and outstanding as of December 31, 2020; 32,159
Series B-1 redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 4,625,783 shares authorized as of December 31, 2020; 4,144,887 shares issued and outstanding as of December 31, 2020; 10,447
Series B-2 redeemable convertible preferred shares, NIS 0.000216 par value per share, none authorized or issued at December 31, 2021; 1,619,024 shares authorized as of December 31, 2020; 71,977 shares issued and outstanding as of December 31, 2020. 290
Total redeemable convertible preferred shares 55,440
SHAREHOLDERS’ EQUITY (DEFICIENCY):    
Ordinary Shares, NIS 0.000216 par value; 130,000,000 and 53,196,505 authorized shares; 63,016,856 and 9,272,428 outstanding shares at December 31, 2021 and 2020, respectively*; [1],[2]
Additional paid-in capital 199,469 1,397
Accumulated deficit (119,646) (61,554)
Total shareholders’ equity (deficiency) [3] 79,823 (60,157)
Total liabilities, redeemable convertible preferred shares and shareholders’ equity (deficiency) $ 105,346 $ 4,405
[1] Prior period results have been retroactively adjusted to reflect the 1:46.25783 stock split and the changes in par value from NIS 0.01 to NIS 0.000216 effected on October 7, 2021. See also Note 12, Share Capital, for details.
[2] Represents less than $1.
[3] Prior period share information has been retroactively adjusted to reflect the 1:46.25783 stock split and the changes in par value from NIS 0.01 NIS to 0.000216 effected on October 7, 2021. See also Note 12, Share Capital, for details.